Clinical trials: Anti-PD1 Antibody
Chronic Hepatitis b, Anti-PD-1 Antibody
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)
Hepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen (HBsAg) loss, is recommended as the ideal endpoint of…
- Conditions
- Chronic Hepatitis b, Anti-PD-1 Antibody, Peg-IFNα
- Trial name
- NCT05771402
- Testing
- Anti-PD-1 antibody, NAs, Peg-IFNα
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Cervical Carcinoma, Chemoradiotherapy
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
This study is a single-center, single-arm, open-phase II clinical study, the main purpose of which is to evaluate the effectiveness and safety of camrelizumab combined with concurrent chemoradiotherapy for early and locally…
- Conditions
- Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1, Immunotherapy
- Trial name
- NCT05311566
- Testing
- Camrelizumab plus Concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Lei Li
DIPG
Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma
Diffuse pontine gliomas are incurable with currently used treatments. based on data stating that progressive tumors inhibit immune system, would try to enhance immune system activity and tumor cell killing.
- Trial name
- NCT01952769
- Testing
- MDV9300
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization
Solid Tumor
A Study of AK131 in Patients With Advanced Solid Tumors
This is a phase Ia/Ib study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK131 in advanced solid tumor patients
- Trial name
- NCT06166888
- Testing
- AK131
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Akeso
Advanced/Metastatic Hepatocellular Carcinoma
IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC
This is a single arm and open-label phase I trial to evaluate the safety, tolerability and efficacy of the oncolytic virus M1 （M1-c6v1）(iv 1×109 CCIC50, 1 dose per day, on day 1-5 each 28 day cycle) combined with anti-PD-1…
- Trial name
- NCT04665362
- Testing
- Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib
- Volunteers
- 10 people
- Sponsor
- Liang Peng
Pancreatic Cancer Stage IV, Pancreatic Cancer Metastatic
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
Aim：Evaluate the efficiency and safety of anti-PD1 antibody (Camrelizumab) combined with Paclitaxel(Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer.
- Trial name
- NCT04674956
- Testing
- Camrelizumab, Paclitaxel(Albumin Bound) and Gemcitabine
- Where
- 6 sites in China
- Volunteers
- 401 people
- Sponsor
- RenJi Hospital
Metastatic Colorectal Cancer
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line…
- Trial name
- daNIS-3 (NCT04952753)
- Testing
- NIS793, Bevacizumab, Modified FOLFOX6
- Where
- 55 sites in United States, Australia and 15 more
- Volunteers
- 204 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Non-small Cell Lung Carcinoma
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
- Trial name
- NCT04042701
- Testing
- Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 115 people
- Sponsor
- Daiichi Sankyo
Triple Negative Breast Cancer
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
Phase I/II, multicenter, open-label, single-arm trial in triple-negative breast cancer patients under first-line neoadjuvant therapy with approved standard of care anti-PD-1 monoclonal antibody (PD-1 inhibitor)…
- Trial name
- NCT06631092
- Testing
- Oral DNA Vaccine
- Where
- 2 sites in Germany
- Volunteers
- 28 people
- Sponsor
- NEC Bio B.V
Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma
Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL
This study evaluates the addition of Sintilimab to current 2nd line salvage therapy of Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).
- Conditions
- Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04659434
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Qian Wenbin
Non Small Cell Lung Cancer
Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Lung cancer is the leading cause of cancer mortality worldwide and in the U.K alone; there are 38,000 new cases of non-small cell lung cancer (NSCLC) a year.
- Trial name
- PARIS (NCT03245177)
- Testing
- Pembrolizumab, Radiotherapy
- Sponsor
- Prof Corinne Faivre-Finn
Nasopharyngeal Cancinoma (NPC)
Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma
This single-arm, phase 2 trial evaluates the efficacy and safety of de-escalated radiotherapy (restricted to the primary tumor, omitting prophylactic neck irradiation) combined with neoadjuvant and adjuvant toripalimab…
- Trial name
- PUPA (NCT07110558)
- Testing
- Without prophylactic neck irradiation, PD-1 antibody (Toripalimab), Cisplatin
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Sun Yat-sen University
Recurrent/ Advanced Stage Endometrial Cancer Patients
An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients
Endometrial carcinoma is the most common malignancy of the female reproductive tract. Most cases are diagnosed at an early stage due to the appearance of symptoms such as postmenopausal bleeding.
- Trial name
- NCT04885413
- Testing
- Niraparib in Combination With Anti-PD1 Antibody
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumor
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS-1811) as monotherapy and in…
- Trial name
- NCT05007782
- Testing
- Denikitug, Zimberelimab
- Where
- 25 sites in United States, Australia and 3 more
- Volunteers
- 304 people
- Sponsor
- Gilead Sciences
Neoplasms Malignant
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with…
- Trial name
- NCT04047290
- Testing
- AK112
- Where
- 7 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Akesobio Australia Pty Ltd
Hepatocellular Carcinoma
Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC
This study is being done to analyze the safety, tolerability, and efficacy of treatment using combination of Pegylated Interferon Alfa-2b and anti-PD-1/PD-L1 antibodies for patients with advanced hepatocellular carcinoma.
- Trial name
- NCT04943679
- Testing
- Anti-PD-1/PD-L1, PEG-Interferon Alfa
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Zhongshan Hospital